AR064406A1 - Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente - Google Patents
Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondienteInfo
- Publication number
- AR064406A1 AR064406A1 ARP070105681A ARP070105681A AR064406A1 AR 064406 A1 AR064406 A1 AR 064406A1 AR P070105681 A ARP070105681 A AR P070105681A AR P070105681 A ARP070105681 A AR P070105681A AR 064406 A1 AR064406 A1 AR 064406A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- alkyl
- compound
- composite
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Epoxy Compounds (AREA)
Abstract
Compuesto calcilítico derivado de (halo-fenilcarboxil)-hidroxietilamina de la formula (1): en la que: X es halogeno; Y es hidrogeno o halogeno; Z es -CO(O)H o -C(O)O-alquilo C1-5; R2 es alquilo C1-5; R3 es fenilo, tienilo, naftilo o dihidroindenilo, donde los restos tienilo y fenilo están opcionalmente sustituidos, independientemente, una o dos veces, con halogeno, alquilo C1-5, alcoxi C1-5 o alquiltio C1-5; y A es un enlace covalente o alquilo C1-5; o una sal farmacéuticamente aceptable del mismo. Composicion farmacéutica que lo comprende y su uso para preparar un medicamento util para antagonizar un receptor de calcio, para tratar una enfermedad o trastorno que comprende una homeostasis osea o mineral anormal como ser osteosarcoma, enfermedad periodontal, curacion de fracturas, osteoartritis, artritis reumatoide, enfermedad de Paget, hipoparatiroidismo, hipercalcemia humoral asociada con malignidad y curacion de fracturas, osteoporosis, osteoporosis o para aumentar los niveles paratiroideos séricos. Dicho uso donde el compuesto de la formula (1) se co-administra con un agente contra la resorcion. Método para sintetizar dicho compuesto y compuesto intermedio correspondiente. Reivindicacion 48: Un método para sintetizar un compuesto de acuerdo con la reivindicacion 1, caracterizado porque comprende las etapas de: (a) tosilacion selectiva de un diol de acuerdo con la formula (2), en la que R8 es alquilo C1-5, y X Y y R2 son como se han definido para la formula (1) en la reivindicacion 1; para producir un tosilato de acuerdo con la formula (3), (b) reaccion del tosilato en presencia de una base para proporcionar un epoxido de acuerdo con la formula (4), y (c) apertura del epoxido con una amina primaria para proporcionar un amino alcohol de acuerdo con la formula (5). Reivindicacion 50: Un intermedio para el método de las reivindicaciones 47 a 49, caracterizado porque se selecciona entre el grupo que consiste en la formula (2), (3) y (4), en las que R8 es alquilo C1-5 y X, Y y R2 son como se han definido en la formula (1) en la reivindicacion 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87043206P | 2006-12-18 | 2006-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064406A1 true AR064406A1 (es) | 2009-04-01 |
Family
ID=39536720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105681A AR064406A1 (es) | 2006-12-18 | 2007-12-18 | Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente |
Country Status (8)
Country | Link |
---|---|
US (1) | US7902394B2 (es) |
EP (1) | EP2120898A4 (es) |
JP (1) | JP2010513564A (es) |
AR (1) | AR064406A1 (es) |
CL (1) | CL2007003688A1 (es) |
TW (1) | TW200845956A (es) |
UY (1) | UY30801A1 (es) |
WO (1) | WO2008077009A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009255156B2 (en) | 2008-06-05 | 2013-03-14 | Asahi Kasei Pharma Corporation | Sulfonamide compound and application thereof |
AU2010310956B2 (en) | 2009-11-02 | 2014-05-08 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
WO2013152476A1 (en) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
US9902751B2 (en) | 2013-12-30 | 2018-02-27 | Mylan Laboratories Limited | Process for the preparation of empagliflozin |
CN105085278A (zh) * | 2015-08-07 | 2015-11-25 | 常州大学 | 一种2-甲基-1-取代苯基-2-丙胺类化合物的制备方法 |
CN106117045A (zh) * | 2016-06-22 | 2016-11-16 | 北京阳光诺和药物研究有限公司 | 一种苯基丁酸的纯化方法 |
CN115710158A (zh) * | 2021-08-23 | 2023-02-24 | 凯特立斯(深圳)科技有限公司 | 一种不对称催化制备替格瑞洛中间体的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1112073A4 (en) * | 1998-08-12 | 2002-10-25 | Smithkline Beecham Corp | CALCILYTIC COMPOUNDS |
CO5180628A1 (es) * | 1999-07-31 | 2002-07-30 | Smithkline Beecham Corp | Compuestos calcioliticos |
AR042132A1 (es) | 2002-11-26 | 2005-06-08 | Smithkline Beecham Corp | Compuesto de 2- hidroxi -3-(2- aril - 1, 1 - dimetiletilamino) propoxifenilo, composicion farmaceutica que lo comprende y uso del mismo para prepararla |
DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
-
2007
- 2007-12-17 UY UY30801A patent/UY30801A1/es not_active Application Discontinuation
- 2007-12-17 TW TW096148160A patent/TW200845956A/zh unknown
- 2007-12-18 JP JP2009543128A patent/JP2010513564A/ja not_active Withdrawn
- 2007-12-18 CL CL200703688A patent/CL2007003688A1/es unknown
- 2007-12-18 AR ARP070105681A patent/AR064406A1/es unknown
- 2007-12-18 WO PCT/US2007/087866 patent/WO2008077009A1/en active Application Filing
- 2007-12-18 EP EP07855230A patent/EP2120898A4/en not_active Withdrawn
- 2007-12-18 US US12/518,482 patent/US7902394B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010513564A (ja) | 2010-04-30 |
CL2007003688A1 (es) | 2008-06-27 |
TW200845956A (en) | 2008-12-01 |
UY30801A1 (es) | 2008-07-03 |
WO2008077009A1 (en) | 2008-06-26 |
EP2120898A4 (en) | 2011-08-03 |
US20100029782A1 (en) | 2010-02-04 |
EP2120898A1 (en) | 2009-11-25 |
US7902394B2 (en) | 2011-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064406A1 (es) | Compuesto de (halo-alquilcarboxi-fenil)-hidroxietilamina composicion farmaceutica que lo comprende su uso para preparar un medicamento, metodo para sintetizar dicho compuesto y compuesto intermedio correspondiente | |
UY30620A1 (es) | Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio | |
UY29962A1 (es) | Compuestos calciliticos | |
CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
BRPI0508622B8 (pt) | compostos de bifenil úteis como antagonistas do receptor muscarínico, composição farmacêutica, processo, medicamento e uso do composto. | |
TW200602338A (en) | Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions | |
DOP2010000103A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
MY145613A (en) | Novel compounds | |
UY27154A1 (es) | Pirimidinas inhibidoras de metaloproteinasa de matriz | |
BRPI0907844B8 (pt) | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos | |
UY29004A1 (es) | Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso. | |
BR112012019551A2 (pt) | moduladores seletivos do receptor de androgênio. | |
BRPI0410117A (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto | |
TN2010000136A1 (en) | Composition comprising sphingosine 1 phosphate (s1p) receptor modulators | |
BRPI0409680A (pt) | análogos de fosfonato anti-cáncer | |
BRPI0415759A (pt) | compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia | |
EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
GT200500119A (es) | Derivados de tetraazabenzo [e] azuleno y sus analogos | |
BR122013028005B8 (pt) | compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos | |
BRPI0817060A2 (pt) | composto, processo para a preparação destes compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são modulados por agonistas receptores de hormônio da tireóide e usos destes compostos | |
BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
AR035348A1 (es) | Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos | |
MY147770A (en) | Novel compounds | |
BRPI0511722A (pt) | 3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina | |
BRPI0705106A (pt) | composições de toner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |